Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme

Vincenzo Sforza, Erika Martinelli, Claudia Cardone, Giulia Martini, Stefania Napolitano, Pietro Paolo Vitiello, Pasquale Vitale, Nicoletta Zanaletti, Alfonso Reginelli, Maurizio Di Bisceglie, Tiziana Pia Latiano, Anna Maria Bochicchio, Fabiana Cecere, Francesco Selvaggi, Fortunato Ciardiello, Teresa Troiani

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: TAS-102 improves overall survival (OS) in patients with metastatic colorectal cancer (mCRC) refractory to standard treatments. However, predictive biomarkers of efficacy are currently lacking. PATIENTS AND METHODS: We treated a cohort of 43 chemorefractory mCRC patients treated with TAS-102, in a single institution expanded access, compassionate use programme. We stratified patients in two groups according to number of cycles received (
Original languageEnglish
Pages (from-to)e000229
JournalESMO Open
Volume2
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme'. Together they form a unique fingerprint.

Cite this